Dechra Declines on $130 Million Services Unit Sale: London Mover

Dechra Pharmaceuticals Plc (DPH) fell the most in almost five years after the U.K. maker of veterinary products announced plans to sell its services unit to Patterson Cos. for 87.5 million pounds ($130 million).

The shares fell as much as 12 percent to 656 pence, the biggest intraday drop since October 2008. The stock was down 8.1 percent at 685 pence as of 11:33 a.m. The volume of trading was more than eight times the three-month daily average.

“The disposal is expected to be earnings dilutive in the short term,” Brian White, an analyst at Shore Capital, said in a note to investors. Even so, “this will mark a significant turning point in the company’s transition to a higher margin animal pharmaceutical company.” Shore Capital kept a buy recommendation on the stock.

The disposal will help the company to focus on higher-margin veterinary products and is expected to take place in mid-August, pending shareholder approval, Stoke-on-Trent, England-based Dechra said in a statement today. The unit is comprised of National Veterinary Services, Dechra Laboratory Services and Dechra Specialist Laboratories.

Dechra’s revenue rose by about 19 percent in the financial year ended June 30, the company said in a trading update today.

Sebastien Jantet, an analyst at Investec Plc, said that was a “touch below” his estimate. He lowered his earnings per share outlook for the year by about 5 percent today because of the sales figure and “an acceleration of investment into the pipeline.”

The disposal “will be dilutive until Dechra redeploys the proceeds,” Jantet said. Investec lowered its recommendation on the stock to hold from add, with a 12-month target price of 700 pence a share.

Reducing Debt

Dechra will use cash from the disposal to reduce net debt, according to today’s statement. The sale will also provide more resources to develop the pharmaceuticals business organically and via acquisition, the company said.

“Today’s disposal removes the ‘poison pill’ from the group and makes the pure-play veterinary pharmaceutical company more attractive to a bidder,” Savvas Neophytou, an analyst at Panmure Gordon, said in a note. Panmure Gordon raised its recommendation on the stock to buy from hold.

Dechra is scheduled to release preliminary full-year results on Sept. 3.

To contact the reporter on this story: Alex Pashley in London at apashley@bloomberg.net

To contact the editor responsible for this story: David Risser at drisser@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.